RU2328308C2 - Комбинирование ингибиторов fbp-азы и антидиабетических средств для лечения диабета - Google Patents

Комбинирование ингибиторов fbp-азы и антидиабетических средств для лечения диабета Download PDF

Info

Publication number
RU2328308C2
RU2328308C2 RU2003103436/15A RU2003103436A RU2328308C2 RU 2328308 C2 RU2328308 C2 RU 2328308C2 RU 2003103436/15 A RU2003103436/15 A RU 2003103436/15A RU 2003103436 A RU2003103436 A RU 2003103436A RU 2328308 C2 RU2328308 C2 RU 2328308C2
Authority
RU
Russia
Prior art keywords
alkyl
aryl
group
aralkyl
alicyclic
Prior art date
Application number
RU2003103436/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2003103436A (ru
Inventor
ПУЛЬЕ Пауль Д. ВАН (US)
ПУЛЬЕ Пауль Д. ВАН
Марк Д. ЭРИОН (US)
Марк Д. ЭРИОН
Тосихико ФУДЗИВАРА (JP)
Тосихико Фудзивара
Original Assignee
Метабэйсис Терапьютикс, Инк.
Санкио Компани, Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Метабэйсис Терапьютикс, Инк., Санкио Компани, Лимитед filed Critical Метабэйсис Терапьютикс, Инк.
Publication of RU2003103436A publication Critical patent/RU2003103436A/ru
Application granted granted Critical
Publication of RU2328308C2 publication Critical patent/RU2328308C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2003103436/15A 2000-07-06 2001-07-05 Комбинирование ингибиторов fbp-азы и антидиабетических средств для лечения диабета RU2328308C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21653100P 2000-07-06 2000-07-06
US60/216,531 2000-07-06

Publications (2)

Publication Number Publication Date
RU2003103436A RU2003103436A (ru) 2004-06-27
RU2328308C2 true RU2328308C2 (ru) 2008-07-10

Family

ID=22807416

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003103436/15A RU2328308C2 (ru) 2000-07-06 2001-07-05 Комбинирование ингибиторов fbp-азы и антидиабетических средств для лечения диабета

Country Status (18)

Country Link
EP (1) EP1372660A2 (no)
JP (1) JP2004508297A (no)
KR (1) KR100854851B1 (no)
CN (2) CN100396283C (no)
AU (2) AU2001273271B2 (no)
BR (1) BR0112212A (no)
CA (1) CA2412142A1 (no)
CZ (1) CZ20035A3 (no)
HU (1) HUP0301830A3 (no)
IL (2) IL153513A0 (no)
MX (1) MXPA02012713A (no)
NO (1) NO20030034L (no)
NZ (1) NZ523227A (no)
PL (1) PL365779A1 (no)
RU (1) RU2328308C2 (no)
SK (1) SK62003A3 (no)
WO (1) WO2002003978A2 (no)
ZA (1) ZA200300044B (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2664422C2 (ru) * 2012-10-08 2018-08-17 ЭлДжи КЕМ, ЛТД. Комбинированный препарат, содержащий гемиглиптин и метформин, и способ его получения

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
DE69910045T2 (de) 1998-09-09 2004-04-22 Metabasis Therapeutics Inc., San Diego Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
CZ20023018A3 (cs) 2000-03-08 2003-01-15 Metabasis Therapeutics, Inc. Nové inhibitory fruktóza-1,6-bisfosfatázy obsahující arylovou skupinu
MXPA04002751A (es) 2001-09-24 2005-09-08 Univ Oregon Health & Science Modificacion del comportamiento de alimentacion.
AU2003201998C1 (en) 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
AU2004309279B2 (en) 2003-12-26 2010-07-15 Kyowa Kirin Co., Ltd. Thiazole derivative
WO2006023515A2 (en) * 2004-08-18 2006-03-02 Metabasis Therapeutics, Inc. Novel thiazole inhibitors of fructose 1,6-bisphosphatase
KR20070086007A (ko) * 2004-12-13 2007-08-27 다이이찌 산쿄 가부시키가이샤 당뇨병의 치료를 위한 의약 조성물
TW200738245A (en) * 2005-08-22 2007-10-16 Sankyo Co Pharmaceutical composition containing FBPase inhibitor
WO2007129522A1 (ja) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited 乾式製造法製剤
US20100076037A1 (en) 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
CN104788350A (zh) * 2014-01-22 2015-07-22 天津大学 一种通过快速冷却结晶法获得甲糖宁药用优势晶型的方法
CN106831437B (zh) * 2016-02-03 2019-06-21 华中师范大学 含硝基乙烯基的酯类化合物及其制备方法和应用
CN114907285B (zh) * 2021-02-10 2023-09-22 华中师范大学 酰化糖精类化合物及其制备方法和应用、降血糖药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03504728A (ja) * 1989-01-24 1991-10-17 ジェンシア・ファーマシュウティカルズ，インコーポレイテッド Ａｉｃａリボシドの放出および血液グルコースの低減のための化合物および方法
AU6452098A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
EP0970095B1 (en) * 1997-03-07 2003-10-29 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
AU6691798A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
US6107274A (en) * 1998-03-16 2000-08-22 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase)
DE69910045T2 (de) * 1998-09-09 2004-04-22 Metabasis Therapeutics Inc., San Diego Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
BR9917005A (pt) * 1998-12-24 2002-04-02 Metabasis Therapeutics Inc Combinação de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete
DE60124861T2 (de) * 2000-01-21 2007-05-10 Novartis Ag Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
GB0015627D0 (en) * 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2664422C2 (ru) * 2012-10-08 2018-08-17 ЭлДжи КЕМ, ЛТД. Комбинированный препарат, содержащий гемиглиптин и метформин, и способ его получения

Also Published As

Publication number Publication date
CZ20035A3 (cs) 2003-05-14
AU2001273271B2 (en) 2006-01-05
CN101301294A (zh) 2008-11-12
JP2004508297A (ja) 2004-03-18
BR0112212A (pt) 2003-12-30
WO2002003978A2 (en) 2002-01-17
IL153513A0 (en) 2003-07-06
NO20030034L (no) 2003-03-05
NO20030034D0 (no) 2003-01-03
PL365779A1 (en) 2005-01-10
SK62003A3 (en) 2003-09-11
MXPA02012713A (es) 2004-09-10
IL153513A (en) 2014-07-31
HUP0301830A3 (en) 2007-10-29
HUP0301830A2 (hu) 2003-11-28
KR100854851B1 (ko) 2008-08-27
CN1599612A (zh) 2005-03-23
CA2412142A1 (en) 2002-01-17
WO2002003978A3 (en) 2003-10-16
NZ523227A (en) 2005-04-29
ZA200300044B (en) 2004-05-06
CN100396283C (zh) 2008-06-25
KR20030031952A (ko) 2003-04-23
EP1372660A2 (en) 2004-01-02
AU7327101A (en) 2002-01-21

Similar Documents

Publication Publication Date Title
US20090197836A1 (en) Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes
RU2328308C2 (ru) Комбинирование ингибиторов fbp-азы и антидиабетических средств для лечения диабета
ES2246586T3 (es) Una combinacion de inhibidores de fbpasa y sensibilizantes de insulina para el tratamiento de la diabetes.
US20080004226A1 (en) Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes
AU2001273271A1 (en) A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
SK8892002A3 (en) Novel bisamidate phosphonate prodrugs, process for their preparation and use thereof
KR20010085776A (ko) 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
KR20020079988A (ko) 신규한 아릴 프럭토스-1,6-비스포스파타제 억제제
LV12686A (en) Method for treating diabetes employing an ap2 inhibitor and combination
US20100056460A1 (en) Combination of organic compounds
AU2006201410A1 (en) A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
EP1552850A2 (en) A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
ERION QUN DANG*, PAUL D. VAN POELJE AND

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
PC4A Invention patent assignment

Effective date: 20080911

MM4A The patent is invalid due to non-payment of fees

Effective date: 20100706

MM4A The patent is invalid due to non-payment of fees

Effective date: 20180706